Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.

Autor: Buisman FE; Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Dr. Molewaterplein 40, 3015, GD, Rotterdam, The Netherlands. f.buisman@erasmusmc.nl., Homs MYV; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, The Netherlands., Grünhagen DJ; Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Dr. Molewaterplein 40, 3015, GD, Rotterdam, The Netherlands., Filipe WF; Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Dr. Molewaterplein 40, 3015, GD, Rotterdam, The Netherlands., Bennink RJ; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Rotterdam, The Netherlands., Besselink MGH; Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Borel Rinkes IHM; Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands., Bruijnen RCG; Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands., Cercek A; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, USA., D'Angelica MI; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA., van Delden OM; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Rotterdam, The Netherlands., Donswijk ML; Department of Nuclear Medicine, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., van Doorn L; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, The Netherlands., Doornebosch PG; Department of Surgery, IJsselland Hospital, Capelle aan den IJssel, The Netherlands., Emmering J; Department of Radiology and Nuclear Medicine, Erasmus MC, Erasmus University, Rotterdam, The Netherlands., Erdmann JI; Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., IJzerman NS; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, The Netherlands.; Department of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Grootscholten C; Department of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Hagendoorn J; Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands., Kemeny NE; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, USA., Kingham TP; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA., Klompenhouwer EG; Department of Radiology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Kok NFM; Department of Surgery, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Koolen S; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, The Netherlands., Kuhlmann KFD; Department of Surgery, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Kuiper MC; Department of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Lam MGE; Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, The Netherlands., Moelker A; Department of Radiology and Nuclear Medicine, Erasmus MC, Erasmus University, Rotterdam, The Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, The Netherlands., Punt CJA; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Te Riele WW; Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands., Roodhart JML; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Swijnenburg RJ; Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Prevoo W; Department of Radiology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Tanis PJ; Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Vermaas M; Department of Surgery, IJsselland Hospital, Capelle aan den IJssel, The Netherlands., Versleijen MWJ; Department of Nuclear Medicine, Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Veuger FP; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Weterman MJ; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Verhoef C; Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Dr. Molewaterplein 40, 3015, GD, Rotterdam, The Netherlands., Groot Koerkamp B; Department of Surgery, Erasmus MC Cancer Institute, Erasmus University, Dr. Molewaterplein 40, 3015, GD, Rotterdam, The Netherlands.

Publikováno v: BMC cancer [BMC Cancer] 2019 Apr 05; Vol. 19 (1), pp. 327. Date of Electronic Publication: 2019 Apr 05.

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

Autor: Kordes S; Department of Medical Oncology, Academic Medical Centre, Amsterdam, Netherlands., Pollak MN; Department of Oncology, McGill University, Montreal, QC, Canada., Zwinderman AH; Department of Statistics, Academic Medical Centre, Amsterdam, Netherlands., Mathôt RA; Department of Hospital Pharmacy, Academic Medical Centre, Amsterdam, Netherlands., Weterman MJ; Department of Medical Oncology, Academic Medical Centre, Amsterdam, Netherlands., Beeker A; Department of Internal Medicine, Spaarne Hospital, Hoofddorp, Netherlands., Punt CJ; Department of Medical Oncology, Academic Medical Centre, Amsterdam, Netherlands., Richel DJ; Department of Medical Oncology, Academic Medical Centre, Amsterdam, Netherlands., Wilmink JW; Department of Medical Oncology, Academic Medical Centre, Amsterdam, Netherlands. Electronic address: j.w.wilmink@amc.uva.nl.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2015 Jul; Vol. 16 (7), pp. 839-47. Date of Electronic Publication: 2015 Jun 08.

A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.

Autor: Kordes S; Department of Medical Oncology, Academic Medical Center Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. s.kordes@amc.uva.nl, Richel DJ, Klümpen HJ, Weterman MJ, Stevens AJ, Wilmink JW

Publikováno v: Investigational new drugs [Invest New Drugs] 2013 Feb; Vol. 31 (1), pp. 85-91. Date of Electronic Publication: 2012 Feb 25.

Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins.

Autor: Weterman MJ; Department of Human Genetics 417, University Hospital Nijmegen, 6500 HB Nijmegen, The Netherlands., van Groningen JJ, Jansen A, van Kessel AG

Publikováno v: Oncogene [Oncogene] 2000 Jan 06; Vol. 19 (1), pp. 69-74.